Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Muscle Invasive Bladder Neoplasms 1Myelodysplastic Syndromes 1Metabolism, Inborn Errors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Immunologic Deficiency Syndromes 1Immunoblastic Lymphadenopathy 1Hemoglobinopathies 1Graft vs Host Disease 1Congenital Bone Marrow Failure Syndromes 1Carcinoma in Situ 1Bone Marrow Failure Disorders 1Anemia, Refractory, with Excess of Blasts 1

Interventions

dodecyl maltoside 2Magnetic Resonance Imaging 2Electrocardiography 2Diphenhydramine 2Acetaminophen 2toripalimab 1fludarabine phosphate 1fludarabine 1enfortumab vedotin 1durvalumab 1cemiplimab 1aldesleukin 1Tomography, X-Ray Computed 1Sampling Studies 1Respiratory Function Tests 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Mitomycin 1Meperidine 1Mastectomy, Subcutaneous 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Hydroxyzine 1Histamine Antagonists 1Granisetron 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma in Situ × Clinical Trials, Phase I as Topic × 1 year × Clear all
NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡